Cite
HARVARD Citation
Sacco, A. et al. (2021). Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet oncology. 22 (6), pp. 883-892. [Online].